AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Strategic Wealth Partners Ltd.

Strategic Wealth Partners Ltd. boosted its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 62.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 158,945 shares of the company's stock after purchasing an additional 61,259 shares during the period. Strategic Wealth Partners Ltd.'s holdings in AstraZeneca were worth $10,414,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Thornburg Investment Management Inc. increased its position in AstraZeneca by 4.0% in the fourth quarter. Thornburg Investment Management Inc. now owns 505,522 shares of the company's stock worth $33,122,000 after buying an additional 19,496 shares in the last quarter. Toronto Dominion Bank lifted its holdings in AstraZeneca by 51.0% in the 4th quarter. Toronto Dominion Bank now owns 27,080 shares of the company's stock worth $1,774,000 after purchasing an additional 9,151 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its stake in AstraZeneca by 43.4% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 288,071 shares of the company's stock worth $18,874,000 after purchasing an additional 87,214 shares during the period. Sphera Funds Management LTD. grew its holdings in AstraZeneca by 18.4% during the 4th quarter. Sphera Funds Management LTD. now owns 225,060 shares of the company's stock valued at $14,746,000 after buying an additional 35,000 shares in the last quarter. Finally, Rafferty Asset Management LLC grew its holdings in AstraZeneca by 31.3% during the 4th quarter. Rafferty Asset Management LLC now owns 196,657 shares of the company's stock valued at $12,885,000 after buying an additional 46,918 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Up 0.6%

Shares of NASDAQ:AZN traded up $0.43 on Friday, reaching $70.38. The company had a trading volume of 2,074,408 shares, compared to its average volume of 5,164,199. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $218.26 billion, a PE ratio of 31.14, a PEG ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The firm's 50 day simple moving average is $69.91 and its 200-day simple moving average is $69.42.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.14. The company had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.06 earnings per share. As a group, analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Morgan Stanley started coverage on shares of AstraZeneca in a research note on Wednesday, February 12th. They set an "overweight" rating for the company. BNP Paribas assumed coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. Finally, UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $88.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.